Urogenital Infections and Inflammations

T.E. Bjerklund Johansen, F. M.E. Wagenlehner, Y.-H. Cho, T. Matsumoto, J. N. Krieger, D. Shoskes, K. Naber

Urinary tract infection in spina bifida

 Yazan F. Rawashdeh 1
Gitte M. Hvistendahl 2


1 Paediatric Urology Section, Department of Urology, Aarhus University Hospital, -, Denmark
2 Aarhus University Hospital, Aarhus, Denmark

Abstract

The urological consequences of spina bifida in children remain challenging for the paediatric urologist and nephrologist. And as the majority of these patients are born with normal urinary tracts and renal function the mainstay of modern management has been to preserve renal function by countering the effects of high bladder pressures, detrusor sphincter dyssynergia and urinary tract infection (UTI) by clean intermittent catheterization (CIC), combined with administering anticholinergics and at times prophylactic antibiotics. Solid evidence derived from well-designed clinical trials for such management protocols are sparse and patently in need of revision and empirical confirmation. Reviewing MEDLINE and The Cochrane Library for English language studies dealing with UTI in paediatric spina bifida over the last decade resulted in 47 hits which were subsequently reviewed shortlisting 22 publications of sufficient relevance and quality for final analysis. Despite the heterogeneous nature of results data indicate that CIC remains a cardinal aspect of management and that regardless of catheter type (single use vs. reusable) no increase in UTI rates were detectable. Furthermore, studies confirm that use of prophylactic antibiotics in paediatric spina bifida patients is superfluous and can safely be discontinued at minimal risk.


Summary of recommendations

  1. Rates of UTI in children with spina bifida is unaffected by the type of catheter used (single use versus reusable or coated hydrophilic versus polyvinylchloride) (GoR A).
  2. Leucocyte esterase tests and dipsticks used for UTI screening purposes can only be used to exclude infection, not to confirm it or confirm significant bacteriuria (GoR B).
  3. In children with spina bifida on CIC, prophylactic antibiotics can safely be discontinued, particularly in male patients with a history of low UTI rates and those without vesico-ureteral reflux (GoR A).
  4. Antibiotic prophylaxis decreases the rate of bacterial colonization, but may change the colonizing flora to more pathogenic bacterial species (GoR B).

1 Introduction

Despite concerted efforts to decrease the incidence of neural tube defects by folic acid fortification, improvement of periconceptional care and prenatal screening about 1 in 2,000 European children are born with spina bifida [1], [2]. Although seemingly low compared to other congenital anomalies such as malformations of the urinary tract for example, spina bifida, which comes in two main forms; spina bifida occulta and the less common but more severe spina bifida aperta (both of which henceforth will be referred to collectively as spina bifida), is a condition which is severe and a subsuming anomaly not only involving the spinal column and CNS, but may also lead to hydrocephalus, paraplegia, mental retardation and neuropathic bowel and bladder. Such a multi-systemic effect renders spina bifida patients severely afflicted and in need of multidisciplinary management and care, posing immense challenges to involved health professionals, care givers and society as a whole not to mention the economic burdens amassed with increasing life expectancy and management options [3].

At birth patients with spina bifida have normal urinary tracts and renal function, so any progressive deterioration of renal function over time occurs due to the effects of neuropathic bladder dysfunction with its attendant detrusor overactivity, detrusor sphincter dyssynergia, and low bladder compliance which results in incomplete bladder emptying, urinary tract infection (UTI) and vesicoureteric reflux [4]. Untreated most of these children will develop end stage renal disease and therefore the mainstay of therapy through the last many decades has been aimed at countering high bladder pressures through clean intermittent catheterization (CIC) combined with the administration of anticholinergics in addition to low dose antibiotic chemoprophylaxis to prevent UTIs.

Other than being a main contributing factor for progressive renal deterioration in patients with spina bifida, recurrent UTIs account for much morbidity and hospitalization in this patient group [3]. A recent analysis of data collected on spina bifida patients over a twenty year observation period showed that 50% of patients developed at least one UTI by 15 months of age increasing to over 80% by the age of 15 years and approximately half the patients developed recurrent UTIs with a high prevalence of Pseudomonas infections and other atypical bacteria [5]. And whereas standardized guidelines for the diagnosis, prevention and management of UTIs in children are under constant review and updating [6] no such consensus exists for children with spina bifida [7]. Lack of consensus on guidelines for managing UTI in this patient subset is undoubtedly multifactorial and most likely stems, at least in part, from the difficulty in designing prospective randomized controlled studies in a patient population often marginalized and with an, at times, unclear chain of command and responsibility with regards to the many specialties assigned to their management. Recognizing the difficulties associated with conducting meaningful randomized controlled studies the Center for Disease Control in association with the Spina Bifida Association recently launched a prospective standardized protocol in the United States in order to optimize urological care by recruiting several large centers treating spina bifida patients, in an effort focused on preventing UTI and renal scarring with the ultimate goal being the preservation of renal function. Prospective data collected will help guide future management protocols and this ambitious study is scheduled to run over a five year period and is a welcome step in the right direction [8].

2 Methods

A systematic literature search was performed for the last 10 years in MEDLINE and the Cochrane library with the following key words: spina bifida, child, urinary tract infection, and antibiotic prophylaxis with the following limitations: English publications and human studies.

A total of 47 publications were identified, which were screened by title and abstract and subsequently supplemented by publications mentioned in selected publications or known by the authors. Studies were analyzed and rated according to the level of evidence (LoE) and the strength of recommendations graded (GoR) according to a system used in the EUA guidelines (2015) modified from the Oxford Centre for Evidence-based Medicine [9].

3 Results and discussion

In all, searches produced 47 hits which after screening by title and abstract and supplementation as previously mentioned resulted in 22 studies incorporated into this overview. Over all there was a rarity of randomized controlled trials or prospective studies on this specific topic. Out of the 22 studies mentioned only two randomized trials, and three nonrandomized comparative trials, were present. The remainder comprised mainly of retrospectives studies in addition to cross sectional reports, surveys, guidelines and expert opinion. It can hence be said that the level of evidence present in the body of literature concerning UTI in paediatric spina bifida patients is poor and patently in need of review based on well-designed prospective randomized control trials which although difficult to attain, constitute the only viable way forward and therefore must be strived for.

4 Definition of UTI

A major point of contention and a prerequisite for any meaningful strategy on preventing UTI in spina bifida patients is the agreement on what constitutes infection. As opposed to normal children where a clear definition exists [6], a lack of consensus on this very basic aspect is noticed when reviewing the relevant spina bifida literature. In a systematic review of spina bifida studies reporting on UTI by Madden-Fuentes et al. only 39.3% of studies published in paediatric journals provided an explicit definition of UTI and the overall definitions were heterogeneous and have not improved in peer reviewed publications over the last five decades as might be expected with the adoption of more rigorous publication criteria. This of course limits any collective conclusions that can be drawn on incidences, management and prevention of UTI from meta-analyzing the literature [10]. Definitions are further complicated by the fact that a majority of spina bifida patients performs CIC and therefore may have colonized urine without actually being infected [11]. Based on their systematic review Madden-Fuentes and colleagues recommend future studies to a priori define UTI as; more than two signs/symptoms (fever >38°C, abdominal pain, new back pain, new or worsening incontinence, pain with CIC or urination in addition to cloudy malodourous urine) AND >100,000 colony forming units per mL urine of a single organism AND >10 white blood cells per high power field on urine microscopy. Although strict this definition can serve as a uniform starting point amenable to refinement and reconsideration based on study outcomes [10]. In a prospective observational study comparing leucocyte esterase tests (LET) and dipsticks with laboratory cultures in spina bifida children on CIC it was found that home screening with LET could be used to exclude significant bacteriuria but had no role in diagnosing infection or significant bacterial growth [12].

5 CIC

Since its introduction in the early seventies CIC has become a cardinal aspect of bladder management in spina bifida patients [13]. Its proactive use in these children is also advocated as studies have shown that early CIC onset decreases the risk of renal function deterioration and bladder augmentation [14], [15], [16], [17]. However CIC is not without complications; such as hematuria, pain, creation of false passages and UTI with some studies even suggesting that proactive CIC may be without long-term benefit and should therefore be reserved to patients where catheterization cannot be avoided [18] [19]. In their retrospective review of 107 patients, from the newborn period to three years of age, Kaye et al. compared incidences of UTI in patients managed by CIC versus patients able to void spontaneously. They found a statistically significant higher incidence of UTI in the CIC group on final follow up leading them to conclude that proactive early onset CIC may not be warranted in infants with spina bifida and should be deferred till a time when it cannot be avoided [19]. Other than its retrospective nature and relatively small cohort, it must be assumed that the study is biased by the fact that patients at the authors’ institute were managed by CIC on “a need basis” and not proactively since they had the two subsets to compare in the same cohort. This weakens any conclusions reached on the effectiveness or lack hereof of proactive CIC protocols. It can further be argued that deviance from the accepted paradigm of early CIC rendered patients more susceptible to UTI when they transitioned from being spontaneous voiders to reliant on CIC as late onset CIC may have been detrimental to bladder function and dynamics. Results and conclusions have therefore to be taken with some reservation pending prospective randomized studies on this topic.

Since its inception, and despite improvements and modifications in catheter design, introduction of single use catheters and pre-lubricated hydrophilic portable catheters, CIC outcomes remain unaltered. This has been documented in a large Cochrane review, where the authors found no convincing evidence that the incidence of UTI is affected by use of aseptic or clean technique, coated or uncoated catheters, single (sterile) or multiple-use catheters, self-catheterization or catheterization by others, or by any other strategy [20]. Similar results have been confirmed in a recent paediatric randomized crossover trial comparing single use hydrophilic coated catheters with multiple use polyvinylchloride catheters with regards to incidences of UTI. The results actually showed a significantly higher incidence of self-reported UTI measured in (person-weeks of UTI) in the hydrophilic single use catheter group but no significant difference in weeks of febrile UTI or antibiotic use between the groups. A plausible explanation put forward for the higher rate of self-reported UTI in the hydrophilic catheter cohort was the issue of slipperiness of the coated hydrophilic catheters leading to difficult catheterization. Overall, the study however simply reiterates the findings of the Cochrane review in paediatric spina bifida patients and underscores that when CIC is done properly catheter type and for that matter technique, have no implications on outcome [21].

6 Antibiotic prophylaxis

The general use of prophylactic antibiotics to prevent infection in patients presumed to be at a higher risk for developing UTI is commonplace albeit controversial. The same goes for patients with spina bifida especially those on CIC. Conventional wisdom has it that periurethral flora originating from the gastrointestinal tract can be introduced into the bladder and ultimately the upper tracts by the passing of a catheter particularly when done multiple times during the day and hence be the cause for bacteriuria and UTI. This has led to an intuitive adoption of antibiotic prophylaxis in an effort to prevent colonization and infection even though it may be that the natural history of colonized urine in spina bifida patients on CIC is completely benign and not a forerunner to UTI as shown in a small observational study by Schlager et al. [22]. In pediatric spina bifida patients there are only a few studies, of proper design and even less with proper strength to have taken on such a claim. In a double blinded placebo controlled cross-over trial of 15 children on CIC receiving either nitrofurantoin or placebo over a period of 11 months it was shown that although symptomatic UTIs dropped significantly to half in the nitrofurantoin group, bacterial colonization in this group, which decreased slightly by about 10%, remained as high as 65% with the flora responsible for colonization changing from the normal Escherichia coli to the more resistant Klebsiella spp. and Pseudomonas spp. that however were not the cause of any infections during the study’s observational period [23]. In a more recent and larger study of 176 patients by Zegers and collaborates, spina bifida paediatric patients on CIC were randomized to either continue or discontinue antibiotic prophylaxis. The main outcomes were in line with those of Schlager et al. [23] in that discontinuation of prophylaxis lead to a significant increase in the rates of asymptomatic significant bacteriuria and afebrile simple UTIs but did not alter the rates of febrile UTIs between the groups. For simple UTI the relative harm of stopping prophylaxis was calculated to be 2.2; that is if two patients discontinued antibiotic prophylaxis for one year, one extra simple nonfebrile UTI would occur. Based on these results the study concluded that spina bifida patients on CIC and low dose antibiotic prophylaxis could safely discontinue chemoprophylaxis in particular males, patients with a history of low UTI rates and those without VUR [24].

7 Further research

Much of the current knowledge on UTI, prevention and management in paediatric spina bifida patients is anecdotal, based on experience, trial and error or grounded in the adult literature. Very little emanates from solid factual and empirical evidence harnessed from clinical trials. Therefore future well-designed studies need to tackle even the most basic principles of management preferably in the setting of randomized controlled trials. Issues that have to be revisited in studies of large paediatric cohorts include those of antibiotic prophylaxis, proactive CIC protocols as there remain a lot of unsettled disputes. Furthermore, ancillary though significant matters of relevance on UTI incidences in these patients have also to be addressed such as bowel management, issues of continence both urinary and fecal in addition to the indications of surgical and neurosurgical intervention and their timing on the long-term outcome and quality of life of this patient category. For such studies to succeed multi-center collaboration, standardization of definitions and treatment protocols are essential prerequisites.

8 Conclusions

Spina bifida patients are born with normal urinary tracts, which places great responsibility on the managing paediatric urologists and nephrologists to preserve renal function in this very vulnerable population. And hence preventing and managing UTI assumes special relevance for meeting these ends. Current evidence supports the need for early onset “preemptive” CIC in order to improve bladder emptying and counter the effects of high detrusor pressures especially when combined with anticholinergics. There is no convincing evidence that suggests that CIC induces UTI with or without concomitant continuous low dose antibiotic prophylaxis with most of the evidence tipping the balance in favor of not needing prophylaxis in these patients and even suggesting that their use might have untoward effects on the natural commensal flora in the urinary tract.


References

[1] Robbins JM, Tilford JM, Bird TM, Cleves MA, Reading JA, Hobbs CA. Hospitalizations of newborns with folate-sensitive birth defects before and after fortification of foods with folic acid. Pediatrics. 2006 Sep;118(3):906-15. DOI: 10.1542/peds.2005-2784
[2] van der Pal-de Bruin KM, van der Heijden PG, Buitendijk SE, den Ouden AL. Periconceptional folic acid use and the prevalence of neural tube defects in The Netherlands. Eur J Obstet Gynecol Reprod Biol. 2003 May 1;108(1):33-9. DOI: 10.1016/S0301-2115(02)00362-7
[3] Armour BS, Ouyang L, Thibadeau J, Grosse SD, Campbell VA, Joseph D. Hospitalization for urinary tract infections and the quality of preventive health care received by people with spina bifida. Disabil Health J. 2009 Jul;2(3):145-52. DOI: 10.1016/j.dhjo.2009.02.001
[4] Shiroyanagi Y, Suzuki M, Matsuno D, Yamazaki Y. The significance of 99mtechnetium dimercapto-succinic acid renal scan in children with spina bifida during long-term followup. J Urol. 2009 May;181(5):2262-6; discussion 2266. DOI: 10.1016/j.juro.2009.01.057
[5] Filler G, Gharib M, Casier S, Lödige P, Ehrich JH, Dave S. Prevention of chronic kidney disease in spina bifida. Int Urol Nephrol. 2012 Jun;44(3):817-27. DOI: 10.1007/s11255-010-9894-5
[6] Mori R, Lakhanpaul M, Verrier-Jones K. Diagnosis and management of urinary tract infection in children: summary of NICE guidance. BMJ. 2007 Aug;335(7616):395-7. DOI: 10.1136/bmj.39286.700891.AD
[7] Zegers BS, Winkler-Seinstra PL, Uiterwaal CS, de Jong TV, Kimpen JL, de Jong-de Vos van Steenwijk CC. Urinary tract infections in children with spina bifida: an inventory of 41 European centers. Pediatr Nephrol. 2009 Apr;24(4):783-8. DOI: 10.1007/s00467-008-1067-8
[8] Routh JC, Cheng EY, Austin JC, Baum MA, Gargollo PC, Grady RW, Herron AR, Kim SS, King SJ, Koh CJ, Paramsothy P, Raman L, Schechter MS, Smith KA, Tanaka ST, Thibadeau JK, Walker WO, Wallis MC, Wiener JS, Joseph DB. Design and Methodological Considerations of the Centers for Disease Control and Prevention Urologic and Renal Protocol for the Newborn and Young Child with Spina Bifida. J Urol. 2016 Dec;196(6):1728-34. DOI: 10.1016/j.juro.2016.07.081.
[9] European Association of Urology. Methodology section. In: European Association of Urology, editor. Guidelines Edition 2015. Arnhem: European Association of Urology; 2015. p. 3. Available from: http://uroweb.org/wp-content/uploads/EAU-Extended-Guidelines-2015-Edn..pdf
[10] Madden-Fuentes RJ, McNamara ER, Lloyd JC, Wiener JS, Routh JC, Seed PC, Ross SS. Variation in definitions of urinary tract infections in spina bifida patients: a systematic review. Pediatrics. 2013 Jul;132(1):132-9. DOI: 10.1542/peds.2013-0557
[11] Sawin KJ, Liu T, Ward E, Thibadeau J, Schechter MS, Soe MM, Walker W; NSBPR Coordinating Committee. The National Spina Bifida Patient Registry: profile of a large cohort of participants from the first 10 clinics. J Pediatr. 2015 Feb;166(2):444-50.e1. DOI: 10.1016/j.jpeds.2014.09.039
[12] Zegers BS, Uiterwaal CC, Verpoorten CC, Christiaens MM, Kimpen JJ, de Jong-de Vos van Steenwijk CC, van Gool JJ. Home screening for bacteriuria in children with spina bifida and clean intermittent catheterization. BMC Infect Dis. 2012 Oct;12:264. DOI: 10.1186/1471-2334-12-264
[13] Rawashdeh YF, Austin P, Siggaard C, Bauer SB, Franco I, de Jong TP, Jorgensen TM; International Children's Continence Society. International Children's Continence Society's recommendations for therapeutic intervention in congenital neuropathic bladder and bowel dysfunction in children. Neurourol Urodyn. 2012 Jun;31(5):615-20. DOI: 10.1002/nau.22248
[14] Edelstein RA, Bauer SB, Kelly MD, Darbey MM, Peters CA, Atala A, Mandell J, Colodny AH, Retik AB. The long-term urological response of neonates with myelodysplasia treated proactively with intermittent catheterization and anticholinergic therapy. J Urol. 1995 Oct;154(4):1500-4. DOI: 10.1016/S0022-5347(01)66914-3
[15] Kaefer M, Pabby A, Kelly M, Darbey M, Bauer SB. Improved bladder function after prophylactic treatment of the high risk neurogenic bladder in newborns with myelomentingocele. J Urol. 1999 Sep;162(3 Pt 2):1068-71. DOI: 10.1016/S0022-5347(01)68069-8
[16] Kasabian NG, Bauer SB, Dyro FM, Colodny AH, Mandell J, Retik AB. The prophylactic value of clean intermittent catheterization and anticholinergic medication in newborns and infants with myelodysplasia at risk of developing urinary tract deterioration. Am J Dis Child. 1992 Jul;146(7):840-3.
[17] Dik P, Klijn AJ, van Gool JD, de Jong-de Vos van Steenwijk CC, de Jong TP. Early start to therapy preserves kidney function in spina bifida patients. Eur Urol. 2006 May;49(5):908-13. DOI: 10.1016/j.eururo.2005.12.056
[18] Woo J, Palazzi K, Dwek J, Kaplan G, Chiang G. Early clean intermittent catheterization may not prevent dimercaptosuccinic acid renal scan abnormalities in children with spinal dysraphism. J Pediatr Urol. 2014 Apr;10(2):274-7. DOI: 10.1016/j.jpurol.2013.09.001
[19] Kaye IY, Payan M, Vemulakonda VM. Association between clean intermittent catheterization and urinary tract infection in infants and toddlers with spina bifida. J Pediatr Urol. 2016 Oct;12(5):284.e1-284.e6. DOI: 10.1016/j.jpurol.2016.02.010
[20] Prieto J, Murphy CL, Moore KN, Fader M. Intermittent catheterisation for long-term bladder management. Cochrane Database Syst Rev. 2014 Sep;(9):CD006008. DOI: 10.1002/14651858.CD006008.pub3
[21] Kiddoo D, Sawatzky B, Bascu CD, Dharamsi N, Afshar K, Moore KN. Randomized Crossover Trial of Single Use Hydrophilic Coated vs Multiple Use Polyvinylchloride Catheters for Intermittent Catheterization to Determine Incidence of Urinary Infection. J Urol. 2015 Jul;194(1):174-9. DOI: 10.1016/j.juro.2014.12.096
[22] Schlager TA, Dilks S, Trudell J, Whittam TS, Hendley JO. Bacteriuria in children with neurogenic bladder treated with intermittent catheterization: natural history. J Pediatr 1995: 126(3):490-6. DOI: 10.1016/S0022-3476(95)70477-9
[23] Schlager TA, Anderson S, Trudell J, Hendley JO. Nitrofurantoin prophylaxis for bacteriuria and urinary tract infection in children with neurogenic bladder on intermittent catheterization. J Pediatr 1998: 132(4):704-8. DOI: 10.1016/S0022-3476(98)70364-6
[24] Zegers B, Uiterwaal C, Kimpen J, van Gool J, de Jong T, Winkler-Seinstra P, Houterman S, Verpoorten C, de Jong-de Vos van Steenwijk C. Antibiotic prophylaxis for urinary tract infections in children with spina bifida on intermittent catheterization. J Urol. 2011 Dec;186(6):2365-70. DOI: 10.1016/j.juro.2011.07.108

The ZB MED – Information Center for Life Sciences, Germany, together with the European Association of Urology (EAU) provided the opportunity to publish a “Living Textbook” on “Urogenital Infections and Inflammations” in an open access form. This “Living Textbook” represents also an update of the Textbook on Urogenital Infections published 2010 by the International Consultation on Urological Infections and the EAU: http://www.icud.info/urogenitalinfections.html.

The “Living Textbook” will cover infections and inflammations of the kidney, the urinary tract, as well as the male and female genital tract considering pathogenesis, diagnostics, treatment, prophylaxis and future aspects. The “Living Textbook” will be structured into about 26 Sections each with two section co-chairs responsible for peer review of the chapters of each section. Each chapter should reflect the background to the topic and highlight all of the critical evidence relating to the subject. The intention is to provide an up to date, concise synthesis of the literature on that topic, and for clinical topics also recommendations based on levels of evidence for contemporary clinical practice, as well as suggested research recommendations.

The editors hope that this “Living Textbook” may become a useful instrument for physicians of different specialties taking care about patients suffering from these diseases.

Truls E. Bjerklund Johansen (Norway),

Florian ME Wagenlehner (Germany),

Yong-Hyun Cho (South Korea),

Tetsuro Matsumoto (Japan),

John N Krieger (USA),

Daniel Shoskes (USA),

Kurt G. Naber (Germany).

Publishing at PUBLISSO

Your chapter will be published at the PUBLISSO platform (https://books.publisso.de).

Information for corresponding authors

It is necessary for all corresponding authors to register at PUBLISSO.
To register at PUBLISSO please click the following link: http://books.publisso.de/publisso_gold/register

After registration, please complete your user profile. Information from your user profile will appear in the published chapter and the authors board of the book (http://books.publisso.de/publisso_gold/book/52). If you are displayed in the authors board, you can be contacted by readers and other professionals. You can also contact other authors of the book for exchange and to build a network.
(If you do not want to be displayed in the authors board, but stay registered, you can disable this feature in your profile settings. In this case, your affiliation (publication data) will be displayed in the published chapter only.)

We kindly ask you to provide the co-authors email addresses in the manuscript so that we can contact them in case of queries.

Information for co-authors

After publication of your chapter, your affiliation (publication data) will be displayed in the published chapter.

If you also want to be displayed in the authors board of the book (http://books.publisso.de/publisso_gold/book/52), we kindly ask you to register at PUBLISSO. If you are displayed in the authors board, you can be contacted by readers and other professionals. You can also contact other authors of the book for exchange and to build a network.

To register at PUBLISSO please click the following link: http://books.publisso.de/publisso_gold/register

If you do not want to be displayed in the authors board of the book, you do not have to register. Your affiliation (publication data) will be displayed in the published chapter only.

Support

If you have any further questions please don’t hesitate to contact the PUBLISSO editorial office:

E-Mail: livingbooks@zbmed.de
Phone: +49 221 478-7093

General

The textbook will be structured in sections with two co-chairs each. Each section will start with an introductory chapter written by the two respective co-chairs presented like an editorial commentary in regard to the following chapters (see proposed contents of the book). The two co-chairs of each section will also peer review all chapters in their section and stimulate a consensus discussion within their section together with the authors and the main editors if needed.

Chapters

Each chapter should reflect the background to the topic and highlight all of the critical evidence relating to the subject. The intention is to provide an up to date, concise synthesis of the literature on that topic, and for clinical topics also recommendations based on levels of evidence for contemporary clinical practice, as well as suggested research recommendations.

Manuscript

Each manuscript should have up to approximately 3,000 words (excluding abstract, tables/figures and references). The abstract should count about 300 words.

Structure

The outline of each chapter should be structured as follows (similar as in the edition 2010, which can be downloaded for free: http://www.icud.info/urogenitalinfections.html):

  1. Abstract
  2. Summary of recommendations*/key notes*
    (*which ever term is more appropriate)
  3. Introduction
  4. Methods
  5. Results
  6. Further research
  7. Conclusions
  8. Acknowledgement
  9. Conflict of interest of each author
  10. References

Citation style

As a citation style, the Vancouver style is preferred.

Please mark your references in the text with square brackets ([1], [2], ...).

Summary of recommendations

We would like to have the Summary of recommendations at the beginning after the abstract (as in the edition 2010). However, we do not expect as in the edition 2010, that each recommendation is also specified according to Level of Evidence and Grade of Recommendation, because such a claim would not only need a systematic literature search (see below), but also a structured discussion in a defined group of experts.

Systematic literature search

A systematic literature search should be performed, at least of PUBMED/MEDLINE but ideally of several relevant databases in addition (like Cochrane CENTRAL) to find recent, high quality systematic reviews and/or primary research studies. It is not expected to perform for all chapters a de novo systematic review, if such reviews are already published recently, but it still may be indicated for some items. For questions relating therapy, it should be focused on evidence from (systematic reviews of) randomized controlled trials if available.

The method of the systematic literature search needs to be fully described in the section “Methods”, e.g.:

“A systematic literature search was performed for the last ... (usually 10) years in MEDLINE, Cochrane etc. with the following key words ... and the following limitations: e.g. UTI, age (adult?), ... clinical studies ... English ... abstract available ... only peer reviewed ...

A total of ... publications were identified, which were screened by title and abstract ... After exclusion of duplicates ... a total of ... were included into the review (analysis), supplemented by citations or known to the authors ... ”.

Clinical topics

Clinical topics should be focused on the importance to clinical practice according to the up to date scientific knowledge as presented in the literature. It should relate to questions/complaints/symptoms of patient/population concerning definition, diagnosis, therapy/prevention, intervention, and outcome in comparison, if different approaches are feasible. Please choose patient-important outcomes and focus on those, which you deem critical for decision-making.

Level of evidence and grade of recommendations

Any recommendation should be based on the level of evidence and the grade of recommendation. For this purpose the following system, modified from the Oxford Centre for Evidence-based Medicine should be used (EAU guidelines 2015):

Level of evidence (LE)

Level Type of evidence
1a Evidence obtained from meta-analysis of randomised trials
1b Evidence obtained from at least one randomised trial
2a Evidence obtained from one well-designed controlled study without randomization
2b Evidence obtained from at least one other type of well-designed quasi-experimental study
3 Evidence obtained from well-designed non-experimental studies, such as comparative studies, correlation studies and case reports.
4 Evidence obtained from expert committee reports or opinions or clinical experience of respected authorities.

Grade of Recommendations (GoR)

Grade Nature of recommendations
A Based on clinical studies of good quality and consistency addressing the specific recommendations and including at least one randomised trial
B Based on well-conducted clinical studies, but without randomised clinical trials
C Made despite the absence of directly applicable clinical studies of good quality

Comments (EAU guidelines 2015)

The aim of assigning a LE and grading recommendations is to provide transparency between the underlying evidence and the recommendation given.

It should be noted that when recommendations are graded, the link between the level of evidence and grade of recommendation is not directly linear. Availability of randomized controlled trials may not necessarily translate into a grade “A” recommendation where there are methodological limitations or disparity in published results.

Alternatively, absence of high level evidence does not necessarily preclude a grade A recommendation, if there is overwhelming clinical experience and consensus. In addition, there may be exceptional situations where corroborating studies cannot be performed, perhaps for ethical or other reasons and in this case unequivocal recommendations are considered helpful for the reader. The quality of the underlying scientific evidence - although a very important factor – has to be balanced against benefits and burdens, values and preferences and costs when a grade is assigned.

Since the same rating system should be used in all chapters, for the sake of brevity the same sentence could be used in “Methods” for all manuscripts, because the rating system will be described in details in the Preface of the book:

“The studies were rated according to the level of evidence and the strength of recommendations graded according to a system used in the EAU guidelines modified from the Oxford Centre for Evidence-based Medicine [1].”

References

[1] European Association of Urology. Guidelines. Methodology section. 2015 ed. Arnhem: European Association of Urology; 2015. p. 3. ISBN/EAN: 978-90-79754-80-9. Available from: http://uroweb.org/wp-content/uploads/EAU-Extended-Guidelines-2015-Edn..pdf

The Living Handbook of Urogenital Infections and Inflammations is issued by:

European Association of Urology
att. Maurice Schlief, EAU executive manager business affairs

P.O.Box 30016
NL-6803 AA Arnhem, The Netherlands

Phone: 0031-26-38.90.680
E-mail: m.schlief@uroweb.org

Editor in Chief

responsible for the contents according to § 5 TMG and § 55 Abs. 2 RStV (Germany):

Kurt G. Naber, MD, PhD
Assoc. Professor of Urology

Technical University of Munich
Karl-Bickleder-Str. 44c
94315 Straubing, Germany

E-mail: kurt.naber@nabers.de

John N. Krieger MD, PhD

University of Washington Section of Urology

more

Daniel Shoskes MD, PhD

Cleveland Clinic Glickman Urological and Kidney Institute

more

Yong-Hyun Cho MD, PhD

St. Mary's Hospital, The Catholic University of Korea Department of Urology

more

Tetsuro Matsumoto MD, PhD

University of Occupational and Environmental Health Department of Urology

more

Florian M. E. Wagenlehner MD, PhD

Justus-Liebig University of Giessen Clinic of Urology and Andrology

more

Truls Erik Bjerklund Johansen MD, PhD

Oslo University Hospital Urology Department

more

Kurt G. Naber MD, PhD

Technical University of Munich

more

Punit Bansal MD, PhD

R G Stone and Super Specialty Hospital
Department of Urology

more

Riccardo Bartoletti

University of Pisa
Department of Translational Research and New Technologies

more

Truls Erik Bjerklund Johansen MD, PhD

Oslo University Hospital
Urology Department

more

PD Dr. med. Gernot Bonkat

University Basel
alta uro AG, Merian Iselin Klinik, Center of Biomechanics & Calorimetry (COB)

more

Prof. Tommaso Cai MD

Santa Chiara Regional Hospital
Dept. of Urology

more

Dr Leyland Chuang

Ng Teng Fong Hospital, National University Health System
Department of Medicine

more

Prof. Milan Cizman

University Medical Centre
Department of Infectious Diseases

more

Alison Crawford MSc

Queen's University
Department of Psychology

more

Pfofessor Svetlana Dubrovina MD, PhD

Rostov Medical State University
Obstetrics and Gynaecology

more

Dr Valerie Huei Li Gan MBBS (S'pore), MRCS (Edin), MMed (Surg), FAMS (Urology)

Singapore General Hospital
Department of Urology

more

Philip Hanno

University of Pennsylvania

more

Ass prof MD Gundela Holmdahl

Queen Silvia Childrens Hospital, Sahlgrens Academy
Pediatric surgery and urology

more

Udo B. Hoyme

HELIOS Hospital Erfurt Ltd.
Department of Gynecology and Obstetrics

more

David Hunstad

Washington University School of Medicine
Pediatrics / Molecular Microbiology

more

Gitte M. Hvistendahl

Aarhus University Hospital

more

Prof. Michael KOGAN M.D., PhD

Rostov State Medical University
Department of Urology

more

Dr Akihiro Kanematsu

Hyogo College of Medicine
Department of Urology

more

Frieder Keller

University Hospital Ulm
Department Internal Medicine 1, Nephrology

more

Professor Katarzyna Kilis-Pstrusinska PhD, MD

Wroclaw Medical University
Department of Pediatric Nephrology

more

MD, PhD Tae-Hyoung Kim

Chung-Ang University
Urology

more

John N. Krieger MD, PhD

University of Washington
Section of Urology

more

Prof Ekaterina Kulchavenya

Novosibirsk Research TB Institute, Novosibirsk State Medical University

more

Dr Christina Kåbjörn Gustafsson

Ryhov Hospital Jönköping
Pathology

more

Dr. Bela Köves

South Pest Teaching Hospital
Department of Urology

more

Iara Linhares

Dr. med. Giuseppe Magistro

Ludwig-Maximilians-University of Munich
Department of Urology

more

Vittorio Magri

ASST-North
Urologic Clinic

more

András Magyar

South-Pest Hospital
Department of Urology

more

Professor Emeritus Brian Morris

University of Sydney
School of Medical Sciences

more

Baerbel Muendner-Hensen

ICA-Deutschland e.V.

more

Stephen F. Murphy

Feinberg School of Medicine, Northwestern University
Department of Urology

more

Kurt G. Naber MD, PhD

Technical University of Munich

more

Prof. Yulia Naboka

Rostov State Medical University
Department of Microbiology

more

Dr. J. Curtis Nickel MD

Queen's University
Department of Urology

more

Professor Ralph Peeker MD PhD

University of Gothenburg
Department of Urology

more

Tamara Perepanova

N.A. Lopatkin Research Institute of Urology and Interventional Radiology

more

Prof. Gianpaolo Perletti M. Clin. Pharmacol.

University of Insubria
Department of Biotechnology and Life Sciences

more

Felice Petraglia

Department of Biomedical, Experimental and Clinical Sciences, University of Florence
Obstetrics and Gynecology

more

Michel Pontari

Temple University School of Medicine
Department of Urology

more

Dr. Jörgen Quaghebeur PhD. Med. Sci.

University Hospital Antwerp and University Antwerp
Department of Urology

more

Yazan F. Rawashdeh

Aarhus University Hospital
Paediatric Urology Section, Department of Urology

more

Professor Claus Riedl MD

-
Urology

more

Matthew Roberts

The University of Queensland
Faculty of Medicine

more

PD Dr. med Guido Schmiemann MPH

Institut für Public Health und Pflegeforschung, Universität Bremen
Abteilung Versorgungsforschung

more

Caroline Schneeberger MD PhD

Academic Medical Center (AMC)

more

Prof. Dr. med. Peter Schneede

Klinikum Memmingen
Department of Urology

more

Aaron C. Shoskes

Des Moines University Medical College of Ostheopathic Medicine

more

Daniel Shoskes MD, PhD

Cleveland Clinic
Glickman Urological and Kidney Institute

more

Prof. Dr. Roswitha Siener

University of Bonn
University Stone Centre, Department of Urology

more

Sofia Sjöström

Queen Silvia Childrens Hospital, Sahlgrens Academy
Pediatric surgery and urology

more

Mathew Sorensen

University of Washington School of Medicine
Department of Urology

more

Prof. Dr. Dr. Walter Ludwig Strohmaier FEBU

Regiomed-Klinikum Coburg. Medical School Regiomed
Urology and Paediatric Urology

more

Satoshi Takahashi

Sapporo Medical University School of Medicine
Department of Infection Control and Laboratory Medicine

more

Professor Paul Anantharajah Tambyah

Yong Loo Lin School of Medicine, National University Hospital
Department of Medicine

more

Peter Tenke

Jahn Ferenc South Pest Teaching Hospital
Department of Urology

more

Praveen Thumbikat


Department of Urology

more

Dr. Jose Tiran Saucedo

IMIGO / Universidad de Monterrey
Obstetrics and Gynaecology

more

Dominic Tran-Nguyen

Des Moines University

more

Dean Tripp

Queen's University
Psychology, Anesthesia & Urology

more

Prof. SEONGHEON WIE

The Catholic University of Korea, St. Vincent's Hospital
Division of Infectious Diseases, Department of Internal Medicine

more

Florian M. E. Wagenlehner MD, PhD

Justus-Liebig University of Giessen
Clinic of Urology and Andrology

more

Assoc. Prof. Christian Wejse

Aarhus University, Aarhus University Hospital
Department of Infectious Diseases/Center for Global Health, Dept of Public Health

more

Prof. Dr. Mete Çek

Trakya University, School of Medicine
Urology

more